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Abstract
Background: PPP1R6 is a protein phosphatase 1 glycogen-targeting subunit (PP1-GTS) abundant in skeletal muscle
with an undefined metabolic control role. Here PPP1R6 effects on myotube glycogen metabolism, particle size and
subcellular distribution are examined and compared with PPP1R3C/PTG and PPP1R3A/GM.
Results: PPP1R6 overexpression activates glycogen synthase (GS), reduces its phosphorylation at Ser-641/0 and
increases the extracted and cytochemically-stained glycogen content, less than PTG but more than GM. PPP1R6
does not change glycogen phosphorylase activity. All tested PP1-GTS-cells have more glycogen particles than
controls as found by electron microscopy of myotube sections. Glycogen particle size is distributed for all cell-types
in a continuous range, but PPP1R6 forms smaller particles (mean diameter 14.4 nm) than PTG (36.9 nm) and GM
(28.3 nm) or those in control cells (29.2 nm). Both PPP1R6- and GM-derived glycogen particles are in cytosol
associated with cellular structures; PTG-derived glycogen is found in membrane- and organelle-devoid cytosolic
glycogen-rich areas; and glycogen particles are dispersed in the cytosol in control cells. A tagged PPP1R6 protein
at the C-terminus with EGFP shows a diffuse cytosol pattern in glucose-replete and -depleted cells and a
punctuate pattern surrounding the nucleus in glucose-depleted cells, which colocates with RFP tagged with the
Golgi targeting domain of b-1,4-galactosyltransferase, according to a computational prediction for PPP1R6 Golgi
location.
Conclusions: PPP1R6 exerts a powerful glycogenic effect in cultured muscle cells, more than GM and less than
PTG. PPP1R6 protein translocates from a Golgi to cytosolic location in response to glucose. The molecular size and
subcellular location of myotube glycogen particles is determined by the PPP1R6, PTG and GM scaffolding.
Background
The main glycogen stores are confined to skeletal muscle
and liver, although glycogen metabolizing machinery is
present in many cell types. In the cell, glycogen is asso-
ciated with protein complexes [1-3] that include glycogen-
metabolizing enzymes such as the synthesizing enzyme
GS, the hydrolyzing enzyme glycogen phosphorylase (GP),
glycogenin, branching enzyme and debranching enzyme,
and regulatory proteins, such as the protein phosphatase
1 (PP1) that directs the metabolism of the glycogen
particle. These glycogen and protein complexes, in the
form of particles or granules, were designated glycosomes
[1,2].
PP1 is the only known serine/threonine phosphatase
that dephosphorylates GS and GP and changes its activa-
tion state [4]. The PP1 catalytic subunit (PP1c) is targeted
to the glycogen particles by glycogen-associated regula-
tory subunits, PP1-GTSs. PP1-GTSs constitute a family
of proteins including PPP1R3A, PPP1R3B, PPP1R3C,
PPP1R3D and PPP1R3E with low amino acid identity,
which is characterized by its conserved PP1c binding
motif (the RVXF motif) [5], a glycogen-binding domain
[6,7] and a PP1-substrate binding domain [7]. PP1-GTSs
display tissue- and specie-specific expression. In human
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skeletal muscle, several members of the PP1-GTS gene
family are expressed: the muscle-specific PPP1R3A/GM/
PP1G/RGL [8,9]; PPP1R3C/PTG/PPP1R5 [9,10] and
PPP1R3B/GL [11], which are expressed mostly in muscle
and liver; the relatively widespread isoform PPP1R3D/
PPP1R6 [9]; and PPP1R3E, most abundant in skeletal
muscle and heart tissue in humans [7]. In contrast, in
rodent skeletal muscle, the PPP1R3B [11] and PPP1R3E
[7] genes are not significantly expressed.
The human PPP1R6 subunit was identified by Arm-
strong et al. [9] in the search for sequences related to the
rat GL and human PPP1R5 proteins in an expressed
sequence tag database. These authors demonstrated that
the PPP1R6 protein specifically binds to purified PP1 and
is associated with glycogen in the glycogen-sarcovesicle
fraction from rabbit skeletal muscle. They detected
PPP1R6 transcripts in all human tissues examined includ-
ing brain, placenta, lung, liver, kidney and pancreas. The
highest levels were found in skeletal muscle and heart. In
a later study, the PPP1R6 gene transcript was detected in
several human cancer cell lines, including small cell and
non-small cell lung cancers, colorectal, gastric and ovarian
cancers, and adult normal lung, colorectal and ovarian tis-
sues, but not normal gastric tissue [12]. Only one previous
study has demonstrated a metabolic functional role of
PPP1R6 in stimulating glycogen accumulation in Chinese
hamster ovary cells stably transformed with the insulin
receptor [13].
In contrast, the metabolic control role of GM and PTG in
the muscle glycogen metabolism has been amply described.
PP1G/RGL/GM regulates basal GS and GP activity ratio in
skeletal muscle, as observed in GM/RGL knockout mice
[14,15] and is essential for GS activation in response to
exercise [14], but not necessary for activation of GS by
insulin [15]. In cultured human myotubes, GM also regu-
lates both GS and GP activities and the effect of activating
GS is enhanced in glucose/glycogen-depleted cells [16].
PTG regulates basal GS activation, is not required for insu-
lin stimulation of GS and does not affect GP activity in ske-
letal muscle of mice bearing a heterozygous deletion of the
PTG gene [17]. In cultured human myotubes, PTG has a
powerful activating effect on GS, which is not glucose-
dependent, and on glycogenesis; whereas it does not affect
GP activity [18]. In this cell system, the effects of GL have
also been reported, i.e. that GL activates GS, regardless of
glucose, and glycogenesis more powerfully than GM, and
does not affect the GP activation state [19].
Even though PP1-GTSs are presumed to contribute to
organizing the glycogen particle [2,3], the ability to target
glycogen particles to a specific subcellular location has
only been suggested for GM/RGL, as it contains a sarco-
plasmic reticulum (SR) binding domain [8,20] and is
found associated with non-junctional SR membranes,
forming a complex with GS and PP1c in rabbit skeletal
muscle [21].
Here we applied metabolic and glycogen cytochemical
techniques to determine the glycogenic effect of PPP1R6;
and used transmission electron microscopy to define the
distribution and morphology of PPP1R6-formed glycogen
particles in cultured skeletal muscle cells, in comparison
with PTG and GM. We also provide information about
the subcellular location of the PPP1R6 protein in cul-
tured myotubes.
Methods
Muscle samples and culture
Muscle samples and myogenic cells came from a cryo-
preserved collection of human skeletal muscle biopsies
described in [22] and obtained with written approval
from the Ethics Committee of the Hospital Sant Joan de
Déu (Barcelona, Spain) according to Spanish legislation
at that time. Myotubes were derived from confluent
myoblast cultures; immediately after the start of myo-
blast fusion, DMEM/M-199 medium (3:1) with 10% FBS
(fetal bovine serum), 10 μg/ml insulin, 4 mM glutamine,
25 ng/ml fibroblast growth factor and 10 ng/ml epider-
mal growth factor was replaced by DMEM/M-199 med-
ium (3:1) with 10% FBS and 10 μg/ml insulin, to further
stimulate differentiation.
Mouse C2C12 myoblasts and 293 cells were grown in
DMEM with 10% FBS. In confluent cultures, C2C12 cell
fusion was stimulated by incubation in DMEM medium
with 10% HS (horse serum). The C2C12-mtRFP cell line
stably expressing the mitochondrial matrix-targeted (mt)
red fluorescent protein (RFP) [23], kindly provided by
Dr. A. Zorzano (Universitat de Barcelona, Spain), was
cultured as the C2C12 cell line.
RNA extraction, reverse transcription (RT) and real-time
PCR
Total RNA was extracted from tissue samples as described
elsewhere [22]. Total RNA from cultured cells was
extracted with the RNeasy Minikit (Qiagen, Valencia,
USA). Extracts were homogenized with a Polytron (Kyne-
matica Polytron, Westbury, USA). A 0.5 μg portion of
total RNA was retrotranscribed with TaqMan RT reagents
from Applied Biosystems (Branchburg, USA) using ran-
dom hexamers. Real-time PCR was performed in the ABI
PRISM 7700 sequence detection system or LightCycler
480 SW 1.5 with the TaqMan universal PCR master mix
or LightCycler 480 Probes Master, respectively, and probes
for human PPP1R3D and rabbit PPP1R3A genes from
Applied Biosystems. b2-microglobulin or 18S rRNA gene
was used as the endogenous control to normalize the
threshold cycle (Ct) or crossing point (Cp) for each probe
assay. Relative gene expression was calculated as 2-ΔCt and
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gene fold change was calculated by the 2-ΔΔCt or 2-ΔΔCp
method. Mean values ± SEM are shown.
Transduction with recombinant adenoviruses
Myotubes were used, 10 days after differentiation-induc-
tion for cultured human myotubes; or 5 days after, for
C2C12 myotubes. Forty-eight hours before the experi-
ments, human myotubes were depleted of insulin; and
24 h before, they were depleted of FBS. C2C12 cells were
depleted of HS, 24 h before the experiments. Myotubes
were transduced with adenoviruses at a multiplicity of
infection of 20 for 4 h (human myotubes) or 2 h (C2C12
myotubes). The Ad-GFP adenovirus encoding the
enhanced green fluorescent protein (EGFP) under the
control of the CMV cytomegalovirus promoter, or the
adenovirus Ad-lacZ, encoding the E. coli ß-galactosidase
gene with a nuclear location signal [24], were used as
controls. An adenovirus containing the cDNA of human
PPP1R3D downstream of the CMV promoter was pre-
pared. To do this, plasmid IRAKp961M1391Q2 from
RZPD (imaGenes GmbH, Berlin, Germany), containing
the cDNA of human PPP1R3D inserted into the pBlue-
scriptR vector, was digested with XhoI and BglII to elicit
the PPP1R3D cDNA band, which was ligated into the Lit-
mus 28i vector (New England BioLabs Inc., Ipswich,
USA) cut with the same restriction enzymes. Then,
PPP1R3D cDNA was excised with XbaI and SalI and
ligated into the pAdCMVIcPA vector (provided by Dr. C.
García-Martínez) cut with the same restriction enzymes.
Five μg of resulting plasmid were cotransfected with
10 μg of pJM17 into 293 cells to generate the adenoviral
construct Ad-R6 [25]. Ad-GM, encoding rabbit GM, and
Ad-PTG, encoding mouse PTG are described in [26].
Ad-MGP encoding rabbit muscle GP is described in [27].
Enzyme activities and glycogen
To measure GS and GP activities, 100 μl of homogeni-
zation buffer consisting of 10 mM Tris/HCl (pH 7.0)
150 mM KF, 15 mM EDTA, 600 mM sucrose, 15 mM
2-mercaptoethanol, 17 μg/l leupeptin, 1 mM benzami-
dine and 1 mM PMSF was used in order to scrape the
cell monolayers off the frozen plates prior to sonication.
The resulting homogenates were used for the determi-
nation of enzyme activities. GP activity was determined
by the incorporation of [U-14C]glucose 1-phosphate into
glycogen in the absence or presence of the allosteric
activator AMP (1 mM) [28]. GS activity was measured
in the absence or presence of 10 mM glucose 6-phos-
phate as described in [29]. An aliquot of the homoge-
nates was used to measure protein concentration with
the Bio-Rad protein assay (Bio-Rad, Hercules, USA).
To assess glycogen synthesis, cells were incubated with
10 mM [U-14C]glucose (0.05 μCi/μmol). To isolate glyco-
gen, cell monolayers were scraped into 100 μl of 30%
KOH and homogenates were boiled for 15 min. An ali-
quot of the homogenates was used to measure protein
concentration with the Pierce BCA protein assay kit
(Thermo Scientific, Rockford, USA). Homogenates were
spotted onto Whatman 3 MM paper; and glycogen was
precipitated by immersing the papers in ice-cold 66%
ethanol. When appropriate, radioactivity in dried papers
was counted in a Beta-radiation counter or papers were
incubated in 0.4 M acetate buffer (pH 4.8) with 25 units/
ml alpha-amyloglucosidase (Sigma-Aldrich, Madrid,
Spain) for 120 min at 37°C to hydrolyze glycogen. In the
latter, glucose released was measured enzymatically with
the Glucose kit from Biosystems (Barcelona, Spain).
Glycogen was stained cytochemically with the periodic
acid/salicyloyl hydrazide (PA-SH) method. Briefly, C2C12
cells grown on coverslips were fixed with methanol at
-20°C for 5 min. After rinsing three times with PBS and
once with distilled water, half the samples were incubated
with 0.1% alpha-amylase (Sigma-Aldrich) for 10 min at
30°C and the other half were not. Then, glycogen was
stained with PA-SH as described in [30], except that they
were not dehydrated and cleared in xylol. Samples were
mounted with Vectashield (Vector laboratories, Burlin-
game, USA) and analyzed with a Leica TCS SP2 confocal
microscope.
Transmission Electron Microscopy
Cells cultured on 10 cm-diameter dishes were fixed with
2.5% glutaraldehyde in 0.1 M phosphate buffer (PB) (pH
7.2) for 1 h and gently rocked at room temperature. Cell
monolayers were scraped into 2 ml of PB. Then, they
were washed with the same buffer and postfixed with 1%
osmium tetroxide in the same buffer at 4°C for 1 h. The
samples were dehydrated in acetone, infiltrated with
Epon resin for 2 days, embedded in the same resin and
polymerized at 60°C for 48 h. Ultrathin sections were
obtained using a Leica Ultracut UCT ultramicrotome
and mounted on Formvar-coated copper grids. They
were stained with 2% uranyl acetate in water and lead
citrate. Then, sections were examined by a JEM-1010
electron microscope (Jeol, Japan). The diameter and
number of glycogen particles were measured by analySIS
software (Olympus Soft Imaging System, Center Valley,
USA).
Western blotting
Aliquots of myotube or 293 cell extracts prepared for
enzyme activity measurement were added with loading
buffer consisting of 50 mM Tris-HCl (pH 6.8), 10 mM
dithiothreitol, 2% SDS, 0.1% bromophenol blue and 10%
glycerol. C2C12 and 293 cell extracts were prepared by
scraping cell monolayers from 6 cm-diameter dishes into
100 μ1 of homogenization buffer consisting of 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
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PMSF, 1 mM NaF, 1 mM Na3VO4, 2 μg/μl benzamidine,
2 μg/μl leupeptin, 1% Nonidet P40 and 1 mM dithiothrei-
tol. Lysates were then gently rocked for 60 min at 4°C.
An aliquot of the total cell extracts was used to measure
protein concentration with the Pierce BCA protein assay
kit. Protein was resolved by SDS/10%-PAGE, and immu-
noblotting was performed with antibodies against human
PP1a, human PPP1R6 or mouse PTG (Santa Cruz Bio-
technology Inc., Santa Cruz, USA), muscle GS or liver/
muscle phospho-GS (Ser-641/0) (Cell Signalling, Dan-
vers, USA), GFP (BD Biosciences, Palo Alto, USA) or
human PPP1R3A (Sigma-Aldrich).
Fusion construct R6-EGFP
A construct containing human PPP1R6 with an EGFP tag
at the C terminus was prepared. To do this, a 910 pb frag-
ment of the PPP1R6 cDNA was isolated from clone
IRAKp961M1391Q2 by performing PCR with Pfu DNA
polymerase. The sequences 5’CCGCGGTACCGTTCC-
GATGAAGTGGATCCAGCTCTCTTC3’and 5’AGA-
GAAGCTTATGTCCAGAGGCCCGAGCTCC3’ were
used, as downstream and upstream oligonucleotides
respectively. Amplification conditions were 3 min at 94°C,
followed by 45 cycles of 1 min at 94°C, 1 min at 65°C and
1 min at 72°C. A final extension was carried out at 72°C
for 10 min. PCR products were purified by 1% agarose gel.
The PCR-amplified fragment was 3’ A-tailed by incubation
with Taq DNA Polymerase in a reaction mixture contain-
ing MgCl2 and dATP, for 15 min at 70°C, and then cloned
into the pGEM-T vector (Promega, Madison, USA) to
generate pGEM-T-R6. Finally, pR6-EGFP was constructed
by cloning the HindIII-KpnI PPP1R6 cDNA excised band
from pGEM-T-R6 into the dephosphorylated pEGFP-N1
vector digested with the same restriction enzymes.
To cytolocate the R6-EGFP construct with the mito-
chondrial network, we used C2C12 mtRFP cells. Cells
grown on coverslips were transfected with 5 μg of pR6-
EGFP with the aid of GeneJuice (Merck Chemicals, Darm-
stadt Germany) and at 48 h post-transfection were fixed
for 15 min with 4% paraformaldehyde in PBS. To cytolo-
cate the R6-EGFP construct with the Golgi complex,
C2C12 cells were cotransfected with 3 μg pR6-EGFP and
3 μg pRFP1-N1-GalT construct, which encodes RFP with
the Golgi targeting domain of b-1,4-galactosyltransferase
(GalTase) [31] (kindly provided by Jennifer Lippincott-
Schwartz of NIH, Bethesda, MD, USA). pEGFP-N1 (BD
Biosciences, San Jose, USA) was used to express EGFP.
Cell preparations were mounted with Vectashield or Pro-
Long Gold (Invitrogen, Paisley, UK) and analyzed with a
Leica TCS SP2 confocal microscope.
Statistical analysis
All data are given as means ± SEM, and the significance
of the difference was analyzed by the Student’s t test.
Values were considered significant at p < 0.05. Results
for gene expression (fold change from the real-time
PCR analysis) were examined with REST (Relative
Expression Software Tool).
Results
Relative expression of the PPP1R6 gene in human
cultured myotubes and skeletal muscle tissue
The mRNA levels of PPP1R6 were analyzed in human
skeletal muscle biopsy samples and in myotubes isolated
from biopsies. In muscle biopsies, relative PPP1R6
mRNA levels (1/2-ΔCt) were lower than levels of the b2-
microglobulin control gene (-19.7 ± 6.0). PPP1R6 gene
expression in cultured myotubes (-453 ± 49) was 28.9
times less (p < 0.01) than in the biopsy tissue samples. In
cultured myotubes, no differences were observed in
PPP1R6 gene expression between cells cultured with glu-
cose or 16 h glucose-deprived cells (data not shown).
Effect of PPP1R6 overexpression on GS and GP activities
Cultured human myotubes were treated with the Ad-R6
adenovirus to overexpress human PPP1R6. Human
PPP1R6 transcript levels were increased by a 2-ΔΔCp fac-
tor of 2167 ± 217 (p = 0.001) in Ad-R6-treated cells, as
assessed by RT and real-time PCR, compared to cells
treated with the Ad-GFP virus and relative to the 18S
rRNA control gene. In an immunoblot analysis the anti-
body against human PPP1R6 protein detected a band in
Ad-R6-treated cells of about 33 kDa (Figure 1A), which
was not shown in cells treated with the Ad-GFP virus,
presumably due to a much lower PPP1R6 protein
content.
The activity of the active form of GS in cell extracts
increased 6 times more in PPP1R6-overexpressing cells
than in cells treated with Ad-GFP, whereas total GS activ-
ity was unchanged (Figure 1B). In contrast, no effects of
PPP1R6 overexpression were observed on GP activity,
either the active form or total activity (Figure 1C). In the
cultured myotubes the brain and liver isoforms of GP are
greater contributors to GP activity, than the muscle GP
isoform, as shown elsewhere [32], due to the drop in
PYGM expression [22]. Thus, we tested whether PPP1R6
affected the activity of the muscle isoform of GP activity
by transducing cells with an adenovirus encoding the mus-
cle isoform of GP (Ad-MGP). In Ad-MGP-treated cells,
the activity of the active form of GP and total GP activity
increased 4 and 16 times, respectively; neither of them was
affected by PPP1R6 delivery (Figure 1C).
Differential regulating effects of PPP1R6, PTG and GM on
GS and glycogen synthesis
We further investigated the activating effect of PPP1R6
on GS and the impact on glycogen accumulation versus
the PP1-GTSs, PTG and GM. Thus, cultured muscle
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cells were transduced with Ad-PTG virus and PTG
expression was confirmed by immunoblot analysis
showing an immunoreactive protein band (of about 36
kDa) not detected in Ad-GFP-transduced cells, as in
[18] (data not shown). GM overexpression was achieved
by transduction with the Ad-GM virus, which increased
the mRNA level of rabbit GM by a factor of 412 ± 34 (p
= 0.001) over cells treated with Ad-GFP and relative to
the 18S rRNA control gene, as assessed by RT real-time
PCR. Immunoblot analysis showed an immunoreactive
protein band (of about 124 kDa) not detected in Ad-
GFP-transduced cells, as in [16] (data not shown).
We analyzed the phospho-GS (Ser-641/0), total muscle
GS and PP1a protein content in cell extracts (Figure 2).
The phospho-GS (Ser-641/0) protein level was slightly
reduced (18%) by PPP1R6 overexpression, compared to
the phosphorylation degree in Ad-GFP-treated cells,
whereas PTG caused a striking reduction (44%) and GM
caused a reduction that did not reach statistical signifi-
cance. In accordance with these observations, an immuno-
blot analysis of muscle GS protein showed a downward
shift in the electrophoretic mobility, indicating depho-
sphorylation of the enzyme, in response to PTG and
PPP1R6. Total muscle GS protein content was increased
by the PP1-GTSs in the order of magnitude: PTG >
PPP1R6 > GM. In consequence, the phospho-GS/total
muscle GS protein ratio was significantly reduced by the
three PP1-GTSs (49% PPP1R6, 81% PTG and 43% GM).
Finally, the total protein content of PP1a, whose transcript
in human tissues is most abundant in skeletal muscle and
heart [33], was also increased by PTG, PPP1R6 and GM in
the same order of magnitude as total muscle GS protein
was.
Next we examined the glucose-dependence of activating
effects on GS activity of the three PP1-GTSs (Figure 3).
Delivery of PPP1R6 enhanced GS activity ratio in both
glucose-replete (23%) and -depleted (56%) cells versus Ad-
GFP-cells, although the effect was stronger under glucose
depletion. Similar glucose dependence was observed for
GM in accordance with our previous data [16]: 17% versus
44% in glucose-replete and -depleted cells, respectively. In
contrast, PTG strongly activated GS, irrespective of glu-
cose presence (4.4-fold) or absence (4.2-fold), as we
showed elsewhere [18].
The effect of PPP1R6 on glycogen synthesis rate was
estimated by the incorporation of radioactively labeled
glucose into glycogen after a period of glucose depriva-
tion. A time-course study showed that, in cells treated
with the control Ad-GFP virus, glucose incorporation
was steady over time, but that in cells overexpressing
PPP1R6 there was progressive enhancement of glucose
deposition into glycogen during the first 8 h, whereas at
24 h the increase was smaller (Figure 4A). Glycogen con-
tent, as assessed after KOH-extraction, ethanol precipita-
tion, hydrolysis with alpha-amyloglucosidase and
quantification of released glucose, was increased by
PPP1R6 overexpression (7-fold) (Figure 4B) much less
than glycogen accumulated in response to PTG overex-
pression (12-fold increment), but more than it was by
GM overexpression (1.4-fold increment).
Figure 1 Effect of PPP1R6 overexpression on GS and GP activity. Cultured human myotubes were transduced with Ad-GFP, Ad-R6 or/and
Ad-MGP and incubated with 25 mM glucose for 48 h. (A) Immunoblot analyses were performed on extracts (20 μg protein) from cells
transduced with Ad-GFP or Ad-R6. Membranes were hybridized with antibody against PPP1R6. Enzyme activities were assessed in cell extracts:
(B) GS activity measured with (black columns, total activity) or without (white columns, activity of the active form) glucose 6-phosphate and (C)
GP activity measured with (black columns, total activity) or without (white columns, activity of the active form) AMP. Data are means ± SEM
from two experiments performed in triplicate. Significance of differences versus cells treated with Ad-GFP under the same incubation conditions:
*p < 0.001 and **p < 0.0001.
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Glycogen was then revealed cytochemically as blue
fluorescent PA-SH stained material in fluorescence
microscopy (Figure 4C). In PPP1R6-overexpressing cells,
diffuse cytoplasmic fluorescence was observed at a
much higher intensity than in cells transduced with the
control virus Ad-lacZ. Fluorescent intensity was,
however, much higher in cells transduced with Ad-PTG,
whereas a fainter signal was detected in cells transduced
with Ad-GM. The PA-SH fluorescently stained material
was drastically removed by digestion with alpha-amylase
in all PP1-GTS-cells, indicating that it was due to glyco-
gen presence.
Figure 2 Immunoblot analysis of GS and PP1 protein content. Cultured human myotubes were transduced with Ad-GFP, Ad-R6, Ad-PTG or Ad-
GM and incubated with 25 mM glucose for 48 h. Immunoblot analyses were performed on cell extracts (20 μg protein for GS and phospho-GS and
5 μg protein for PP1). Membranes were hybridized with antibodies against: (A) phospho-GS (Ser-641/0), (B) muscle GS and (D) PP1a. (A, B, D) A
representative image is shown. Bands were quantified with a LAS-3000 (FujiFilm). Data are means ± SEM from three experiments performed in
duplicate. Significance of differences versus cells treated with Ad-GFP under the same incubation conditions: *p < 0.05 and **p < 0.01.
Figure 3 GS activity ratio in glucose-replete and -depleted cells. Cultured human myotubes were transduced with Ad-GFP, Ad-R6, Ad-PTG
or Ad-GM and then incubated with (white columns) or without (black columns) 25 mM glucose for 24 h. GS activity ratio (without glucose 6-
phosphate/with glucose 6-phosphate) was measured in cell extracts. Data are means ± SEM from five experiments performed in duplicate.
Significance of differences: versus cells treated with Ad-GFP under the same incubation conditions, *p < 0.05 and **p < 0.0001; cells without
glucose versus with glucose for any viral treatment, †p < 0.01 and ‡p < 0.0001.
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Glycogen granules were examined in myotube sections
by transmission electron microscopy (Figure 5). In control
Ad-GFP-cells, glycogen was revealed as spherical dense
particles (Figure 5A and 5B) scattered through the cytosol
(Figure 5A). The number of particles counted in control
cells was 39 ± 12 particles/μm2. The mean diameter of
particles was 29.2 ± 0.7 nm and the majority of particles
were within 20 to 30 nm although some of them reached
more than 50 nm, as shown in Figure 6. In PPP1R6-over-
expressing cells, there were many more dense round parti-
cles (288 ± 20 particles/μm2, p < 0.0001), whose mean
diameter 14.4 ± 0.4 nm (p < 0.0001) was smaller, while the
range was from 7 to 24 nm. These PPP1R6-derived parti-
cles appeared as membrane-, vesicle- or organelle-asso-
ciated granules. In PTG-cells a marked increment in the
number of particles was also seen (202 ± 38 particles/μm2,
p < 0.005), but particles had a much larger diameter of
36.9 ± 0.7 nm (p < 0.0001) and sizes ranged from higher
than 23 to more than 50 nm. These were located in the
cytosol in large areas filled with glycogen particles, which
appeared devoid of organelles and not surrounded by a
membrane. Finally, GM-overexpression caused a smaller
rise in the number of glycogen particles (75 ± 7 particles/
μm2, p < 0.05), which were concentrated in clusters close
to certain organelles, notably the endoplasmic reticulum,
and the subsarcolemma. The average size of GM-derived
glycogen granules was 28.3 ± 0.7 nm and diameters ranged
from 17 to 45 nm.
Intracellular location of the fusion protein R6-EGFP
We analyzed by computational methods the possible
intracellular location of PPP1R6. The Hum-mPLoc [34]
server that predicts subcellular location at multiple loca-
tions predicted Golgi membrane location for PPP1R6,
while the Golgi predictor [35] server implemented for
Type II transmembrane proteins gave a 26.11 index
(threshold 20.00) for Golgi location. However, the Tar-
getP 1.1 [36] server, which also predicts the subcellular
location of eukaryotic proteins, gave a 0.695 probability
that the sequence contains a mitochondrial targeting
peptide, while the MitoProtII server [37], which predicts
mitochondrially-imported proteins, gave a 0.8578 prob-
ability that human PPP1R6 protein would be transported
to mitochondria.
Then, we constructed a fusion protein of PPP1R6 with
a C-terminal EGFP flag (R6-EGFP). Expression of the
Figure 4 Glycogen synthesis and content. Cultured human myotubes were: (A) transduced with Ad-GFP (▲) or Ad-R6 (■) and incubated with
glucose-deprived medium for 18 h, then with 10 mM [U-14C]glucose for the times indicated and harvested to quantify the radioactivity
associated with glycogen; (B) transduced with Ad-GFP, Ad-R6, Ad-PTG or Ad-GM, incubated with 25 mM glucose for 48 h and harvested to assess
glycogen content. (A, B) Data are means ± SEM from three experiments performed in duplicate. Significance of differences versus cells treated
with Ad-GFP: *p < 0.05 and **p < 0.001. (C) C2C12 cells were transduced with Ad-lacZ, Ad-R6, Ad-PTG or Ad-GM and incubated with 25 mM
glucose for 72 h. Fixed cell monolayers were treated without (-) or with (+) alpha-amylase and glycogen stained with fluorescent PA-SH. A
representative image is shown.
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fusion protein and its glycogenic activity was confirmed
after transfection of the plasmid encoding R6-EGFP into
293 cells. Immunoblot analysis with anti-PPP1R6 anti-
body showed a band of about 60 kDa molecular weight,
higher than the endogenous PPP1R6, in cells transfected
with R6-EGFP and not in those transfected with EGFP
(data not shown). A band of this same size was also
recognized by the anti-GFP antibody in R6-EGFP cells,
whereas a band of about 27 kDa was revealed in EGFP-
cells (Figure 7A). In 293 cells expressing the R6-EGFP
construct glycogen synthesis (120 ± 2 nmol glucose
incorporated/mg protein) was higher (p < 0.0001) than in
EGFP-cells (55 ± 0.4 nmol glucose incorporated/mg
protein).
Figure 5 Glycogen particles. Cultured human myotubes were transduced with Ad-GFP, Ad-R6, Ad-PTG or Ad-GM and incubated with 25 mM
glucose for 48 h and then fixed and stained for observation of glycogen particles in transmission electronic microscopy. Representative images
are shown: (A) image of myotubes obtained at × 40000 magnification, in which glycogen granules appear as dense spheroid particles, and (B) a
detail of glycogen granules (arrows). Scale bars = 100 nm.
Figure 6 Diameter of glycogen particle. The graphics plot the diameter of each measured glycogen granule (at least 70 quoted granules for
each condition) in cultured human myotubes transduced with Ad-GFP, Ad-R6, Ad-PTG or Ad-GM and incubated with 25 mM glucose for 48 h.
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Figure 7 Cytolocation of R6-EGFP. (A) 293 cells were transfected with 5 μg of plasmids encoding EGFP or R6-EGFP with the aid of GeneJuice,
at 48 h post-transfection a Western blotting analysis was performed on cell extracts (30 μg protein) and membranes were hybridized with an
antibody against GFP. (B) (a to f) C2C12 myoblasts were cotransfected with pR6-EGFP and pRFP1-N1-GalT, at 48 h post-transfection, cells were
incubated with 25 mM glucose (a to c) or without glucose (d to f) for 16 h and a colocation analysis of EGFP and RFP was performed; (g to l)
C2C12-mtRFP myoblasts were transfected with pR6-EGFP, at 48 h post-transfection, cells were incubated with 25 mM glucose (g to i) or without
glucose (j to l) for 16 h and then colocation analysis of EGFP and RFP was performed. The image shows the fluorescent signal of EGFP (a, d, g, j)
and RFP (b, e, h, k) and the colocation of the signal of EGFP and RFP (c, f, i, l).
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To assess whether PPP1R6 was located at the Golgi
complex, we cotransfected R6-EGFP and the Golgi mar-
ker, RFP1-N1-GalT, into C2C12 myoblasts incubated with
and without glucose. As shown in Figure 7B, in glucose-
replete cells, R6-EGFP appeared throughout the cytosol
with a diffuse pattern and no colocation with RFP1-N1-
GalT was found. In glucose-depleted cells, R6-EGFP
showed a similar cytosol pattern plus a punctuated pattern
clustered around the nucleus that was colocated with the
Golgi marker. The Golgi marker RFP1-N1-GalT displayed
a compact structure in the perinuclear region mainly cov-
ering one of the nucleus poles in glucose-replete cells and
appeared in punctuate structures surrounding the nucleus
in glucose-depleted cells, according to the fact that ATP
depletion induces the Golgi apparatus disassembly [38].
To examine whether PPP1R6 was located at the mito-
chondria, R6-EGFP was delivered to C2C12 mtRFP myo-
blasts, which express a mitochondrial matrix-targeted RFP
(Figure 7B). No colocation of R6-EGFP was observed with
mt-RFP either in glucose-replete or -depleted cells. As a
control, we transfected C2C12 and C2C12 mtRFP myo-
blasts with a plasmid encoding EGFP and we observed
that this protein was located both in the cytoplasm and
nucleus of glucose-replete or -depleted cells and that it
was not colocated with either the mitochondrial matrix-
targeted or Golgi-targeted RFP (data not shown).
Discussion
PPP1R6 was originally described as a glycogen-associated
PP1 regulatory subunit with wide tissue expression and
most common in humans in skeletal muscle and heart [9].
Here we report the lower expression of the PPP1R6 gene
in human cultured myotubes than in skeletal muscle tis-
sue. In this regard, PPP1R6 resembles PPP1R3C and dif-
fers from the PPP1R3B gene, whose expression is
maintained in culture, and also from the muscle-specific
PPP1R3A gene, whose expression is almost suppressed
[19]. Therefore, on the basis of our data from this and the
earlier study [19], the relative differential gene expression
is PPP1R3C > PPP1R3A > PPP1R6 > PPP1R3B in human
skeletal muscle tissue and PPP1R3C > PPP1R3B > PPP1R6
> PPP1R3A in cultured human myotubes.
In cultured myotubes, PPP1R6 activated GS and reduced
its phosphorylation at Ser-641/0, also referred to as site 3a,
in a less powerful manner than PTG, but stronger than
GM. GS may be phosphorylated at nine or more sites [39],
but the Ser-641/0 site is crucial for the regulation of GS
activity and is extensively regulated by various effectors
[4]. The selectivity of PP1 for the different sites of GS
phosphorylation has not been established, but it has been
proposed that PP1-GTSs may confer such selectivity [4].
Our data provide evidence that the degree of dephosphor-
ylation of the Ser-641/0 site achieved in response to
PPP1R6, PTG or GM is tightly associated with that of GS
activation, thereby suggesting a similar strong control of
enzyme activity through the modulation of the phosphory-
lation of this site by these PP1-GTSs. The activating effect
of PPP1R6 on GS was enhanced by glucose/glycogen
depletion, as also observed for GM [16] but not PTG [18].
In fact, glycogen content is a strong regulator of GS and
high glycogen content impairs insulin-stimulated activa-
tion of this enzyme, as reviewed in [4]. PPP1R6 did not
exert any effect on the cultured myotube GP activity,
either the endogenously expressed isoforms, which are
predominantly the brain (PYGB) and liver (PYGL) iso-
forms [32], or the overexpressed muscle (PYGM) isoform.
Like PPP1R6, neither does PTG affect endogenous myo-
tube GP activity [18], whereas GM inactivates GP [16]. As
PPP1R6 markedly activated GS in myotubes, it exerted a
potent glycogenic effect. This was seen by the increases in
the rate of glycogen synthesis; by an increase in the net
glycogen content, as quantified after KOH extraction and
ethanol precipitation; and cytochemically, by an increase
in the glycogen stained as blue fluorescent PA-SH
material.
Glycogen accumulation in response to PPP1R6 was less
than that achieved with PTG but higher than with GM.
Cellular glycogen is complexed with proteins, including
glycogen metabolizing enzymes, PP1 and PP1-GTSs [3], in
the form of particles or granules, also named glycosomes
[1,2]. The morphology of these granules was originally
defined by Drochmans [40] as a-, b- and g-types. The a
particles, commonly found in mammalian liver, are
agglomerates of b-particles, have a rosette appearance and
large diameters [1], in the order of 100 nm [40]. Single
b-particles are found in most normal tissues, including
skeletal muscle [1], have a spheroid shape and diameters
ranging from 15 to 40 nm. The g-particles are about 3 nm
in diameter and are subunits of b- and a-particles [1].
Glycogen particle sizes in skeletal muscle cells have been
consistently shown to follow a continuous distribution
pattern. In human skeletal muscle, diameters range from
10 to 44 nm and a mean value of 25 nm at rest [41] and
from 8 to 43 nm and a mean particle size of about 13 nm
after exercise [42]. In cultured rat myotubes, these parti-
cles range from above 15 to above 40 nm (mean value of
29.4 nm) in glycogen-replete cells or from above 10 to
below 40 nm (mean value of 24.9 nm) in glycogen-
depleted ones [43]. Strikingly, here we show that, despite
being in a continuous range, the size distribution pattern
of glycogen particles is determined by PP1-GTS scaffold-
ing, with average diameters in the order of PPP1R6 < GM
< PTG. In control myotubes most glycogen particles cor-
responded to the b-type, with a mean diameter of 29.2
nm. No particles smaller than about 20 nm were observed,
but a few above 42 nm were found. Notably, the detection
limit for small glycogen granules is estimated to be 5-10
nm (at 20000 × magnification) [42], while the predicted
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maximum size limit of a granule is 42 nm, consisting of 12
tiers of carbohydrate [3]. PPP1R6 generated small gran-
ules, with a mean diameter of 14.4 nm, with most of the
granules falling below 20 nm and many between 7 and 15
nm. These granules resembled the g-type in the formation
of filamentous alignments [40]. GM-derived glycogen par-
ticles showed an intermediate mean diameter of 28.3 nm
and most were between 20 and 40 nm, which corresponds
to the b-particle classification. PTG produced the largest
particles, with a mean diameter of 36.9 nm and values ran-
ging from 25 to 50 nm. Many of these particles looked like
b-type ones, but we observed a few supramolecular clus-
ters with a rosette-like shape that resembled a-particles.
In fact, the larger a-type glycogen particles have not been
observed in mammalian tissues other than liver [40]. Since
PTG is expressed abundantly in liver, in rats [44] and
humans [9], we speculate that it induces the formation of
a-particles in this tissue. In this regard, b particles are sug-
gested to be covalently bonded to form a-particles
through a hitherto unsuspected enzyme process operative
in the liver [45], which could be tissue-dependent.
The number of glycogen particles was increased by the
three PP1-GTSs tested. PPP1R6 and PTG induced the
greatest increases in particle numbers and quantified gly-
cogen accumulation. The rise in particle numbers per cell
area for PPP1R6 was higher than with PTG, although
quantification of extracted or cytochemically stained gly-
cogen was not greater, probably because PTG-derived par-
ticles have bigger size and tend to form agglomerations of
single b-particles. GM caused the smallest increase in the
number of particles per cell area, which fits with glycogen
quantification data. In fact, early muscle glycogen resynth-
esis has been shown to also rely on the synthesis of new
particles. Elsner et al. [43] suggested that during early gly-
cogen resynthesis in fasted cultured myotubes, new glyco-
gen molecules are formed while there is a modest increase
in glycogen particle diameter. Graham and coworkers [42]
showed that, during recovery from prolonged exercise,
resynthesis of muscle glycogen in humans is characterized
initially by an increase in number and no change in parti-
cle size and later by an increase in particle size but not in
number.
The subcellular distribution of glycogen-particles pro-
moted by either PP1-GTS has distinct patterns. In
PPP1R6-myotubes, granules were closely associated with
cellular components. In GM-myotubes, granules accumu-
lated near the endoplasmic reticulum, which is consistent
with GM association with SR via an SR-binding sequence
in its C-terminal region [8,20,21]; however, granules also
appeared in other locations, preferentially subsarcolem-
mal ones. In fact, two forms of GM, an SR-associated
form and a cytosolic glycogen-associated form, can be
distinguished in rat skeletal muscle extracts [46]. In con-
trast, PTG caused the accumulation of glycogen granules
in large clusters located in central areas of the cytosol
devoid of cellular organelles. In control cells, glycogen
granules were distributed throughout the cytosol. Since
in control myotubes the PPP1R3C gene is the most
expressed gene (of PPP1R3A, PPP1R3B, PPP1R3C and
PPP1R6 genes) and PTG is strongly glycogenic, it can be
argued that glycogen particles in these cells are mainly
PTG-derived, which may explain their preferential cyto-
solic location. Smaller granules were observed in control
myotubes than in PTG-overexpressing cells, probably
due to much lower glycogen accumulation in the former.
We cannot rule out, however, a role for the still unstu-
died PPP1R3E protein. In the skeletal muscle tissue of
humans [3,41,47,48] and rats [49], electron microscopy
studies have shown compartmental distribution of glyco-
gen particles in three main regions: subsarcolemmal,
intermyofibrillar and intramyofibrillar. In the subsarco-
lemmal location, clustered accumulations are observed at
the level of mitochondria and SR [47], and nuclei and
mitochondria [41]. Aneurally cultured human myotubes
are not fully differentiated, and likely this influences the
pattern of cellular glycogen distribution. However, with
PPP1R6 and GM we observed clustering of glycogen
granules to the membrane of myotube organelles.
Finally, here we applied computational scanning of the
PPP1R6 protein sequence to gain insight into its potential
subcellular distribution. These analyses revealed a high
probability that PPP1R6 is located at the Golgi complex or
imported into the mitochondria. We thus analyzed the
subcellular distribution of PPP1R6 tagged at the C-termi-
nus with EGFP. The tagged PPP1R6 showed a diffuse pat-
tern in the cytosol in glucose-replete and -depleted cells
and a punctuate pattern clustered around the nucleus in
glucose-depleted cells only. Since no colocation of tagged
PPP1R6 with the mitochondrial-targeted RFP was
observed, irrespective of glucose incubation, no support
for the mitochondrial export premise was obtained.
Neither was colocation of the tagged PPP1R6 with the
Golgi-targeted RFP in glucose-replete C2C12 myoblasts.
However, in glucose-depleted myoblasts the two proteins
overlapped in the perinuclear region, according to the
sequence-based prediction of PPP1R6 location in the
Golgi complex. Therefore, our data suggest that PPP1R6
translocates in response to glucose from the Golgi com-
plex to a cytosolic location, where it is associated with gly-
cogen. Along this line of argument, PPP1R6 present in the
glycogen/sarcovesicle fraction isolated from rabbit skeletal
muscle is specifically associated with glycogen, since it is
released by digestion of glycogen with a-amylase [9]. The
role that PPP1R6, or PPP1R6-targeted PP1, may exert in
the Golgi apparatus in glucose-depleted myotubes is
beyond the scope of this study. For instance, PP1 activity
was previously reported to be essential in regulating
vacuolar fusion and endoplasmic reticulum-to-Golgi and
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endocytic vesicular trafficking in the yeast Saccharomyces
cerevisiae [50]. Noteworthy, in muscle cells GS also shows
differential intracellular distribution as a function of glyco-
gen content. In skeletal muscle, GS translocates from a
glycogen-enriched membrane fraction to the cytoskeleton
as glycogen content is lowered [51] or it is found asso-
ciated with spherical structures formed by actin cytoskele-
ton rearrangement after glycogen-depletion [52,53]. In
cultured C2C12 cells, muscle GS concentrates in the
nucleus in the absence of glucose and translocates to the
cytosol in response to glucose [54]. These data suggest
that after cellular glycogen depletion, some glycogen-asso-
ciated proteins, such as PPP1R6 and GS, may translocate
to diverse cell compartments.
Conclusions
PPP1R6 gene expression has been described as highest in
skeletal muscle and heart; however its relative transcript
levels are much lower than those of other PP1-GTSs in
both human skeletal muscle tissue and primary cultured
muscle. Although PPP1R6 has low protein sequence
homology with human GM and PPP1R5 proteins [9], it
exerts a powerful glycogenic effect in cultured muscle
cells, more than GM and less than PTG. PPP1R6 translo-
cates in response to glucose from the Golgi complex to
the cytosol, where it is presumably associated with glyco-
gen. Finally, we show that the pattern of size and subcellu-
lar distribution of glycogen particles is differentially
determined by PPP1R6, PTG or GM used as molecular
scaffolding, which reveals that PP1-GTSs confer glycogen
granule regulation.
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